NPS Pharmaceuticals Among 100 Best Places to Work in New Jersey for Second Consecutive Year -- Employees highlight company’s culture and commitment to core values in survey -- Business Wire BEDMINSTER, N.J. -- April 26, 2013 NPS Pharmaceuticals, Inc. (NASDAQ: NPSP), a biopharmaceutical company pioneering and delivering therapies that transform the lives of patients with rare diseases worldwide, has been named one of the Best Places to Work in New Jersey. This is the second consecutive year that NPS has received this honor, which is awarded annually by NJBIZ – the state’s weekly business journal – to New Jersey’s top 100 employers who demonstrate dedication to their employees’ growth and quality of life. “Being recognized again as one of the best places to work in New Jersey is truly an honor and is a reflection of the culture-by-design that we have created at NPS,” said Francois Nader, M.D., president and chief executive officer of NPS Pharmaceuticals. “I’m especially proud that in the survey many employees recognized NPS’ dedication to our core values – integrity, respect, excellence, personal ownership, teamwork, entrepreneurial spirit and fun. Living these values has directly contributed to our quest to bringing life-changing therapies to patients with rare disorders.” Approximately 75 percent of the Best Places to Work in New Jersey evaluation is based on an employee survey that measures workplace experience and sentiment. The other 25 percent of the evaluation is based on the company's workplace policies, practices, philosophy, systems and demographics. Data from the surveys and applications, which are submitted by many companies throughout New Jersey, are analyzed by the Best Companies Group to determine the final rankings. One-hundred companies split into two groups – 62 small/medium-sized companies (15-249 employees), including NPS, and 38 large-sized companies (more than 250 employees) – make up the Best Places to Work in New Jersey. The 2013 Best Places to Work in New Jersey rankings were announced at an awards dinner and ceremony on Thursday, April 25 at the Hilton East Brunswick. About NPS Pharmaceuticals NPS Pharmaceuticals is a biopharmaceutical company pioneering and delivering therapies that transform the lives of patients with rare diseases worldwide. The company’s lead product, Gattex^® 0.05 mg/kg/d (teduglutide [rDNA origin]) for injection is FDA-approved for the treatment of adult patients with short bowel syndrome (SBS) who are dependent on parenteral support. NPS is also developing Natpara^® (rhPTH[1-84]) for the treatment of adult hypoparathyroidism and subject to the resolution of certain manufacturing issues, expects to submit its Biologic License Application (BLA) to the FDA in 2013. NPS's earlier stage pipeline includes two calcilytic compounds, NPSP790 and NPSP795, with potential application in rare disorders involving increased calcium receptor activity, such as autosomal dominant hypocalcemia with hypercalciuria (ADHH). NPS complements its proprietary programs with a royalty-based portfolio of products and product candidates that includes agreements with Amgen, GlaxoSmithKline, Janssen Pharmaceuticals, and Kyowa Hakko Kirin. Additional information about NPS is available through its corporate website, http://www.npsp.com. “NPS,” “NPS Pharmaceuticals,” “Gattex,” “Natpara”, “Preotact”, and “Revestive” are the company's trademarks. Disclosure notice Statements made in this press release, which are not historical in nature, constitute forward-looking statements for purposes of the safe harbor provided by the Private Securities Litigation Reform Act of 1995. These statements are based on the company's current expectations and beliefs and are subject to a number of factors and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. Forward looking statements include, but are not limited to, statements concerning our future financial performance. Risks associated to the company's business include, but are not limited to, the risks associated with any failure by the company to successfully commercialize Gattex, including the risk that physicians and patients may not see the advantages of Gattex and may therefore be reluctant to utilize the product, the risk that private and public payers may be reluctant to cover or provide reimbursement for Gattex, the risk that the company may be unable to resolve the manufacturing issue in order to submit its BLA for Natpara, the risks associated with the company's strategy, global macroeconomic conditions, the impact of changes in management or staff levels, the effect of legislation effecting healthcare reform in the United States, as well as other risk factors described in the company's periodic filings with the U.S. Securities and Exchange Commission, including its Annual Report on Form 10-K and Form 10-Qs. All information in this press release is as of the date of this release and NPS undertakes no duty to update this information, whether as a result of new information, future events or otherwise. Contact: NPS Pharmaceuticals, Inc. Susan M. Mesco 908-450-5516 (office) email@example.com www.npsp.com
France's Iliad Confirms Interest in T-Mobile U.S.
NPS Pharmaceuticals Among 100 Best Places to Work in New Jersey for Second Consecutive Year